Gilead Sciences is a major biopharmaceutical company that develops and manufactures prescription drugs and biologic therapies. Its recent lobbying filings show it spends to influence U.S. federal policy on regulation of prescription drugs and biologics. Filings list one outside firm used and about $300,000 reported across four filings, most recently in January 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
DAVID RUDLOFF
The latest disclosures for this client.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q2JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
JOHN HERZOG
JEFFREY J. KIMBELL & ASSOCIATES, INC.
JOHN R RAY
JEFFREY J. KIMBELL & ASSOCIATES, INC.
KEITH STUDDARD
JEFFREY J. KIMBELL & ASSOCIATES, INC.
LAURA KEMPER
JEFFREY J. KIMBELL & ASSOCIATES, INC.
mr JEFFREY J KIMBELL
JEFFREY J. KIMBELL & ASSOCIATES, INC.
mr KENNETH LEE HODGE
JEFFREY J. KIMBELL & ASSOCIATES, INC.
BRETT MEEKS
JEFFREY J. KIMBELL & ASSOCIATES, INC.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q4JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q3JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q2JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q1